Pulmonx Corporation
Organization details
- Legal name
- Pulmonx Corporation
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Redwood City
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LUNG
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001127537
Board of directors
-
Alissa Hsu Lynch · DirectorSince 2023
-
Dana G. Mead Jr. · DirectorSince 2023
-
Daniel P. Florin · DirectorSince 2023
-
Georgia Melenikiotou · DirectorSince 2023
-
Glendon E. French III · Director · President and CEOSince 2023
-
Richard Ferrari · DirectorSince 2023
-
Steven S. Williamson · Director · PRESIDENT AND CEOSince 2024
-
Thomas William Burns · DirectorSince 2023
-
Tiffany Sullivan · DirectorSince 2023
Chief executives
Outstanding · grade A
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 89
14.8% a year in revenue
20% of the scoring weight is on file. Figures cover December 2023 – December 2025.
Director election results
Annual meeting of June 4, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.9%
-
94.9%
-
95.4%
Board connections
6 of this board's directors also sit on 7 other boards. 6 are in the same sector.
-
Inspire Medical Systems Inc. Same sectorvia Dana G. Mead Jr. and Georgia Melenikiotou
-
Edap TMS S.A. Same sectorvia Glendon E. French III
-
Glaukos Corporation Same sectorvia Thomas William Burns
-
Heartbeam Inc. Same sectorvia Richard Ferrari
-
Mobia Medical Inc. Same sectorvia Dana G. Mead Jr.
-
Tenon Medical Inc. Same sectorvia Richard Ferrari
- via Alissa Hsu Lynch
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $547,892
- 55 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 1, 2026 | Glendon E. French III Director, Officer (President and CEO) | Open-market sale | −4,098 | $2.26 | $9,261 |
| Sep 1, 2026 | Lehman David Aaron Officer (General Counsel) | Open-market sale | −3,807 | $2.26 | $8,604 |
| Sep 1, 2026 | Rose Geoffrey Beran Officer (Chief Commercial Officer) | Open-market sale | −2,213 | $2.26 | $5,001 |
| Sep 1, 2026 | Radhakrishnan Srikanth Officer (Chief Science & Techn. Officer) | Open-market sale | −2,643 | $2.26 | $5,973 |
| Sep 1, 2026 | Glendon E. French III Director, Officer (President and CEO) | Open-market sale | −37,784 | $2.26 | $85,392 |
| Sep 1, 2026 | Lehman David Aaron Officer (General Counsel) | Open-market sale | −2,224 | $2.26 | $5,026 |
| Sep 1, 2026 | Rose Geoffrey Beran Officer (Chief Commercial Officer) | Open-market sale | −2,390 | $2.26 | $5,401 |
| Sep 1, 2026 | Radhakrishnan Srikanth Officer (Chief Science & Techn. Officer) | Open-market sale | −2,121 | $2.26 | $4,793 |
| Sep 1, 2026 | Lehman David Aaron Officer (General Counsel) | Open-market sale | −3,476 | $2.26 | $7,856 |
| Sep 1, 2026 | Rose Geoffrey Beran Officer (Chief Commercial Officer) | Open-market sale | −1,530 | $2.26 | $3,458 |
| Sep 1, 2026 | Radhakrishnan Srikanth Officer (Chief Science & Techn. Officer) | Open-market sale | −3,618 | $2.26 | $8,177 |
| Sep 1, 2026 | Lehman David Aaron Officer (General Counsel) | Open-market sale | −4,827 | $2.26 | $10,909 |
| Sep 1, 2026 | Rose Geoffrey Beran Officer (Chief Commercial Officer) | Open-market sale | −1,746 | $2.26 | $3,946 |
| Sep 1, 2026 | Radhakrishnan Srikanth Officer (Chief Science & Techn. Officer) | Open-market sale | −5,863 | $2.26 | $13,250 |
| Jun 5, 2026 | Thomas William Burns Director | Grant or award | +40,000 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Pulmonx Corporation
Who is the CEO of Pulmonx Corporation?
Steven S. Williamson has been Pulmonx Corporation's PRESIDENT AND CEO since March 2024.
How many directors are on Pulmonx Corporation's board?
Pulmonx Corporation's board has 9 directors: Alissa Hsu Lynch, Dana G. Mead Jr., Daniel P. Florin, Georgia Melenikiotou, Glendon E. French III, Richard Ferrari, Steven S. Williamson, Thomas William Burns and Tiffany Sullivan.
Are Pulmonx Corporation insiders buying or selling shares?
Over the last 12 months, Pulmonx Corporation insiders made no open-market purchases and sold $547,892 of shares in 55 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="pulmonx-corporation"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.